1. A new article discusses potential benefits and ongoing concerns regarding complement inhibition therapy in geographic atrophy, including efficacy, safety, and regulatory decisions.
2. Pegcetacoplan and avacincaptad pegol have demonstrated promise in slowing disease progression, but also uncertainties.
3. These medications have reduced geographic atrophy lesion growth in phase III trials, but methodological concerns and risks associated with frequent intravitreal injections remain, the researchers in the article note, as well as concerns regarding regulatory approvals and clinical adoption.
4. Lack of measurable functional improvement in current GA therapies is a key limitation.
5. There is a need for research that explores alternative therapeutic targets beyond complement inhibition.

Source: JAMA Ophthalmology